Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Oct;66(10):894-902.
doi: 10.1136/thoraxjnl-2011-200154. Epub 2011 Jun 16.

Genome-wide association study of smoking behaviours in patients with COPD

Collaborators, Affiliations
Clinical Trial

Genome-wide association study of smoking behaviours in patients with COPD

Mateusz Siedlinski et al. Thorax. 2011 Oct.

Abstract

Background Cigarette smoking is a major risk factor for chronic obstructive pulmonary disease (COPD) and COPD severity. Previous genome-wide association studies (GWAS) have identified numerous single nucleotide polymorphisms (SNPs) associated with the number of cigarettes smoked per day (CPD) and a dopamine beta-hydroxylase (DBH) locus associated with smoking cessation in multiple populations. Objective To identify SNPs associated with lifetime average and current CPD, age at smoking initiation, and smoking cessation in patients with COPD. Methods GWAS were conducted in four independent cohorts encompassing 3441 ever-smoking patients with COPD (Global Initiative for Obstructive Lung Disease stage II or higher). Untyped SNPs were imputed using the HapMap (phase II) panel. Results from all cohorts were meta-analysed. Results Several SNPs near the HLA region on chromosome 6p21 and in an intergenic region on chromosome 2q21 showed associations with age at smoking initiation, both with the lowest p=2×10(-7). No SNPs were associated with lifetime average CPD, current CPD or smoking cessation with p<10(-6). Nominally significant associations with candidate SNPs within cholinergic receptors, nicotinic, alpha 3/5 (CHRNA3/CHRNA5; eg, p=0.00011 for SNP rs1051730) and cytochrome P450, family 2, subfamily A, polypeptide 6 (CYP2A6; eg, p=2.78×10(-5) for a non-synonymous SNP rs1801272) regions were observed for lifetime average CPD, however only CYP2A6 showed evidence of significant association with current CPD. A candidate SNP (rs3025343) in DBH was significantly (p=0.015) associated with smoking cessation. Conclusion The authors identified two candidate regions associated with age at smoking initiation in patients with COPD. Associations of CHRNA3/CHRNA5 and CYP2A6 loci with CPD and DBH with smoking cessation are also likely of importance in the smoking behaviours of patients with COPD.

Trial registration: ClinicalTrials.gov NCT00292552.

PubMed Disclaimer

Conflict of interest statement

COMPETING INTERESTS

No competing interests: MS, AG

GlaxoSmithKline employee: WA, XK

NHLBI grant: JEH, THB

NIH grant: MHC, EKS, JDC

GlaxoSmithKline grant: EKS, DAL, PB

COPD Foundation grant: EKS, JDC

GlaxoSmithKline consulting fee or honorarium and support for travel to meetings for the study or other purposes: EKS, DAL

COPD Foundation support for travel to meetings for the study or other purposes: EKS, JDC

AstraZeneca and GlaxoSmithKline - payment for lectures including service on speakers bureaus and consultancy (outside the submitted work): EKS, PB

Pfizer - payment for lectures including service on speakers bureaus and consultancy (outside the submitted work): PB

GlaxoSmithKline - board membership, consultancy, payment for lectures including service on speakers bureaus and consultancy (outside the submitted work): DAL

Boehringer Ingelheim consultancy (outside the submitted work): DAL

GlaxoSmithKline fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like: DAL

Consulting fee or honorarium from AstraZeneca, Novartis, Otsuka: SIR

Grant from AstraZeneca, Biomarck, Centocor, Mpex, Nabi, Novartis, Otsuka: SIR

Almirall, Novartis, Nycomed, Pfizer board membership (outside the submitted work): SIR

Almirall, AstraZeneca, Boehringer Ingelheim, California Allergy Society, Creative Educational Concept, France Foundation, GlaxoSmithKline, Information TV, Network for Continuing Education, Novartis, Nycomed, Pfizer - travel/accommodations expenses covered or reimbursed (outside the submitted work): SIR

Able Associates, Adelphi Research, APT Pharma/Britnall, Aradigm, AstraZeneca, Boehringer Ingelheim, Chiesi, CommonHealth, Consult Complete, COPDForum, Data Monitor, Decision Resource, Defined Health, Dey, Dunn Group, Easton Associates, Equinox, Gerson, GlaxoSmithKline, Infomed, KOL Connection, M. Pankove, MedaCorp, MDRx Financial, Mpex, Oriel Therapeutics, Otsuka, Pennside, PharmaVentures, Pharmaxis, Price Waterhouse, Propagate, Pulmatrix, Reckner Associates, Recruiting Resources, Roche, Schlesinger Medical, Scimed, Sudler and Hennessey, TargeGen, Theravance, UBC, Uptake Medical, VantagePoint Mangement - consultancy (outside the submitted work): SIR

Figures

Figure 1
Figure 1. Regional association plots of two loci including SNPs associated with age at smoking initiation with meta-analytic p<10−6
Dots correspond to meta-analyzed SNPs. Color of dots corresponds to r2 (linkage disequilibrium (LD) coefficient in the HapMap II CEU population; grey dots correspond to SNPs with missing LD information) relative to the most significantly associated SNP (depicted with diamond) in the region i.e. rs13408379 (top figure) and rs9380362 (bottom figure).
Figure 2
Figure 2. Regional association plots of the candidate loci centered on CHRNA3 (top) and CYP2A6 (bottom) and their associations with lifetime average number of cigarettes smoked per day
Dots correspond to meta-analyzed SNPs. Color of dots correspond to r2 (linkage disequilibrium (LD) coefficient in the HapMap II CEU population; grey dots correspond to SNPs with missing LD information) relative to the most significantly associated SNP in the region (depicted with diamond) i.e. rs1051730 in the CHRNA3 (top figure) and rs1496402 (bottom figure; the second top SNP in this region is a nonsynonymous (Leu160His) rs1801272 SNP in the CYP2A6). CHRNA3=alpha-nicotinic acetylcholine receptor 3; CYP2A6=Cytochrome P450 2A6

References

    1. Vink JM, Posthuma D, Neale MC, et al. Genome-wide linkage scan to identify Loci for age at first cigarette in Dutch sibling pairs. Behav Genet. 2006;36:100–11. - PubMed
    1. Li MD, Cheng R, Ma JZ, et al. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction. 2003;98:23–31. - PubMed
    1. Batra V, Patkar AA, Berrettini WH, et al. The genetic determinants of smoking. Chest. 2003;123:1730–9. - PubMed
    1. Schnoll RA, Johnson TA, Lerman C. Genetics and smoking behavior. Curr Psychiatry Rep. 2007;9:349–57. - PubMed
    1. Han S, Gelernter J, Luo X, et al. Meta-analysis of 15 genome-wide linkage scans of smoking behavior. Biol Psychiatry. 67:12–9. - PMC - PubMed

Publication types

MeSH terms

Associated data